 Jason Gien
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 34 | 2023 | 186 | 9.900 |
Why?
| | Extracorporeal Membrane Oxygenation | 16 | 2023 | 241 | 3.600 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 637 | 2.500 |
Why?
| | Hypertension, Pulmonary | 16 | 2022 | 1727 | 2.150 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2023 | 329 | 1.950 |
Why?
| | Persistent Fetal Circulation Syndrome | 7 | 2016 | 132 | 1.700 |
Why?
| | rho-Associated Kinases | 5 | 2016 | 80 | 1.670 |
Why?
| | Infant, Newborn | 45 | 2023 | 5043 | 1.600 |
Why?
| | Pulmonary Artery | 14 | 2018 | 1015 | 1.460 |
Why?
| | Neovascularization, Physiologic | 6 | 2013 | 173 | 1.440 |
Why?
| | Endothelial Cells | 10 | 2018 | 681 | 1.380 |
Why?
| | Endothelin-1 | 4 | 2016 | 167 | 1.360 |
Why?
| | Nitric Oxide | 8 | 2020 | 823 | 1.260 |
Why?
| | Tracheostomy | 5 | 2016 | 101 | 1.080 |
Why?
| | Lung | 15 | 2023 | 3558 | 1.070 |
Why?
| | Respiration, Artificial | 4 | 2016 | 529 | 0.940 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2023 | 28 | 0.920 |
Why?
| | Infant | 24 | 2023 | 7959 | 0.910 |
Why?
| | Ostomy | 1 | 2023 | 3 | 0.910 |
Why?
| | PPAR gamma | 2 | 2013 | 182 | 0.820 |
Why?
| | Sheep | 14 | 2018 | 764 | 0.810 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 104 | 0.800 |
Why?
| | Patient Care Team | 3 | 2016 | 517 | 0.790 |
Why?
| | Retrospective Studies | 34 | 2023 | 12542 | 0.780 |
Why?
| | Length of Stay | 7 | 2019 | 962 | 0.780 |
Why?
| | Water-Electrolyte Imbalance | 4 | 2022 | 26 | 0.750 |
Why?
| | Ductus Arteriosus, Patent | 3 | 2023 | 50 | 0.730 |
Why?
| | Reperfusion Injury | 1 | 2023 | 255 | 0.720 |
Why?
| | Blood Gas Analysis | 2 | 2021 | 72 | 0.700 |
Why?
| | Prenatal Diagnosis | 2 | 2020 | 167 | 0.690 |
Why?
| | Vasodilator Agents | 4 | 2016 | 302 | 0.680 |
Why?
| | Transportation of Patients | 1 | 2020 | 52 | 0.660 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2023 | 498 | 0.660 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 290 | 0.640 |
Why?
| | Pregnancy | 19 | 2023 | 5517 | 0.610 |
Why?
| | Bronchodilator Agents | 1 | 2020 | 239 | 0.610 |
Why?
| | Shock, Septic | 1 | 2020 | 186 | 0.600 |
Why?
| | Continuity of Patient Care | 2 | 2016 | 253 | 0.560 |
Why?
| | Humans | 60 | 2023 | 114623 | 0.550 |
Why?
| | Trachea | 1 | 2018 | 224 | 0.520 |
Why?
| | Ventilator Weaning | 1 | 2016 | 33 | 0.520 |
Why?
| | Hemodynamics | 4 | 2022 | 1012 | 0.510 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2015 | 235 | 0.500 |
Why?
| | Umbilical Arteries | 1 | 2015 | 41 | 0.500 |
Why?
| | Infant, Premature | 10 | 2023 | 476 | 0.490 |
Why?
| | Radial Artery | 1 | 2015 | 66 | 0.490 |
Why?
| | Sepsis | 2 | 2020 | 509 | 0.490 |
Why?
| | Herniorrhaphy | 3 | 2020 | 48 | 0.480 |
Why?
| | Vasoconstrictor Agents | 2 | 2018 | 112 | 0.480 |
Why?
| | Female | 41 | 2023 | 59466 | 0.480 |
Why?
| | Central Nervous System Diseases | 1 | 2014 | 61 | 0.450 |
Why?
| | Infant, Extremely Premature | 1 | 2014 | 57 | 0.450 |
Why?
| | Vasopressins | 1 | 2014 | 56 | 0.450 |
Why?
| | Weight Gain | 1 | 2017 | 453 | 0.440 |
Why?
| | Patient Discharge | 4 | 2021 | 771 | 0.430 |
Why?
| | Oxygen Consumption | 1 | 2015 | 588 | 0.420 |
Why?
| | Hypotension | 1 | 2014 | 116 | 0.420 |
Why?
| | Hospital Mortality | 3 | 2021 | 776 | 0.420 |
Why?
| | Hernia, Diaphragmatic | 3 | 2021 | 67 | 0.420 |
Why?
| | Echocardiography | 5 | 2023 | 553 | 0.420 |
Why?
| | Gastrostomy | 3 | 2023 | 91 | 0.410 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1394 | 0.410 |
Why?
| | Developmental Disabilities | 1 | 2014 | 237 | 0.390 |
Why?
| | Enzyme Activation | 1 | 2012 | 785 | 0.360 |
Why?
| | Communication | 1 | 2016 | 744 | 0.360 |
Why?
| | Animals, Newborn | 5 | 2023 | 778 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3039 | 0.350 |
Why?
| | Kidney | 6 | 2023 | 1188 | 0.330 |
Why?
| | Pulmonary Alveoli | 4 | 2014 | 373 | 0.320 |
Why?
| | Bacteremia | 3 | 2019 | 160 | 0.320 |
Why?
| | Endothelium, Vascular | 3 | 2013 | 843 | 0.320 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2022 | 222 | 0.310 |
Why?
| | Animals | 18 | 2023 | 31694 | 0.300 |
Why?
| | Survival Rate | 4 | 2022 | 1644 | 0.290 |
Why?
| | Lung Volume Measurements | 3 | 2023 | 45 | 0.290 |
Why?
| | Sulfonamides | 3 | 2016 | 445 | 0.290 |
Why?
| | Fetal Growth Retardation | 3 | 2018 | 467 | 0.280 |
Why?
| | Male | 25 | 2022 | 55554 | 0.270 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2022 | 358 | 0.270 |
Why?
| | Fetal Diseases | 1 | 2007 | 147 | 0.270 |
Why?
| | Risk Factors | 9 | 2021 | 8628 | 0.260 |
Why?
| | Morbidity | 2 | 2023 | 280 | 0.260 |
Why?
| | Receptors, Endothelin | 2 | 2016 | 49 | 0.250 |
Why?
| | Urinary Tract Infections | 4 | 2019 | 134 | 0.250 |
Why?
| | Cells, Cultured | 8 | 2014 | 3881 | 0.250 |
Why?
| | Fetus | 6 | 2023 | 699 | 0.240 |
Why?
| | Signal Transduction | 6 | 2018 | 4509 | 0.240 |
Why?
| | Treatment Outcome | 7 | 2022 | 9084 | 0.230 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 66 | 0.230 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2537 | 0.220 |
Why?
| | Endotoxins | 2 | 2015 | 211 | 0.220 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 17 | 0.220 |
Why?
| | Pulmonary Veins | 2 | 2014 | 81 | 0.220 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2013 | 184 | 0.220 |
Why?
| | Fundoplication | 2 | 2020 | 53 | 0.210 |
Why?
| | Umbilical Cord | 1 | 2023 | 80 | 0.210 |
Why?
| | Parturition | 1 | 2023 | 54 | 0.210 |
Why?
| | Pulmonary Circulation | 4 | 2014 | 407 | 0.210 |
Why?
| | Gestational Age | 7 | 2021 | 759 | 0.200 |
Why?
| | Surgical Flaps | 2 | 2023 | 121 | 0.200 |
Why?
| | Tracheobronchomalacia | 1 | 2022 | 14 | 0.200 |
Why?
| | Tracheomalacia | 1 | 2022 | 19 | 0.200 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 32 | 0.200 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1477 | 0.190 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 22 | 0.190 |
Why?
| | Guanylate Cyclase | 2 | 2011 | 32 | 0.180 |
Why?
| | Benzoates | 2 | 2011 | 38 | 0.180 |
Why?
| | Interactive Ventilatory Support | 1 | 2020 | 2 | 0.180 |
Why?
| | Serotonin | 2 | 2013 | 292 | 0.180 |
Why?
| | Analgesia | 1 | 2021 | 82 | 0.180 |
Why?
| | Infant Mortality | 2 | 2019 | 91 | 0.170 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 58 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 497 | 0.170 |
Why?
| | Heart Failure | 2 | 2022 | 1945 | 0.170 |
Why?
| | Rats | 4 | 2023 | 4958 | 0.160 |
Why?
| | Heart Atria | 1 | 2020 | 107 | 0.160 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2016 | 27 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2015 | 3531 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 180 | 0.160 |
Why?
| | Child | 8 | 2022 | 18404 | 0.160 |
Why?
| | Diuretics | 2 | 2018 | 66 | 0.160 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 192 | 0.160 |
Why?
| | Asphyxia Neonatorum | 1 | 2018 | 15 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2015 | 2186 | 0.150 |
Why?
| | Intensive Care Units, Neonatal | 5 | 2018 | 176 | 0.150 |
Why?
| | Prospective Studies | 4 | 2022 | 6217 | 0.150 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2018 | 25 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 197 | 0.150 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 82 | 0.150 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 249 | 0.150 |
Why?
| | Survival Analysis | 2 | 2020 | 1211 | 0.140 |
Why?
| | Administration, Inhalation | 2 | 2016 | 641 | 0.140 |
Why?
| | Blood Vessels | 2 | 2016 | 180 | 0.140 |
Why?
| | Brain Diseases | 1 | 2018 | 124 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 3 | 2016 | 2218 | 0.140 |
Why?
| | Injections, Intraperitoneal | 1 | 2016 | 99 | 0.140 |
Why?
| | Infant Care | 1 | 2016 | 42 | 0.140 |
Why?
| | Expectorants | 1 | 2016 | 24 | 0.130 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 44 | 0.130 |
Why?
| | Bacterial Infections | 1 | 2018 | 218 | 0.130 |
Why?
| | Ventilators, Mechanical | 1 | 2016 | 52 | 0.130 |
Why?
| | Cross Infection | 1 | 2018 | 197 | 0.130 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2016 | 141 | 0.130 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.130 |
Why?
| | Databases, Factual | 5 | 2018 | 1124 | 0.130 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 397 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 216 | 0.130 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 16 | 0.130 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1796 | 0.130 |
Why?
| | Steroids | 1 | 2016 | 144 | 0.130 |
Why?
| | Preoperative Care | 1 | 2017 | 319 | 0.130 |
Why?
| | Piperidines | 1 | 2016 | 160 | 0.120 |
Why?
| | Receptors, Calcitriol | 1 | 2015 | 53 | 0.120 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 41 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 268 | 0.120 |
Why?
| | Bleomycin | 1 | 2016 | 228 | 0.120 |
Why?
| | Oligopeptides | 1 | 2016 | 236 | 0.120 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 253 | 0.120 |
Why?
| | Catalase | 1 | 2015 | 118 | 0.120 |
Why?
| | Positive-Pressure Respiration | 1 | 2015 | 68 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2015 | 292 | 0.120 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 57 | 0.120 |
Why?
| | Arteriovenous Fistula | 1 | 2014 | 29 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2015 | 201 | 0.120 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 82 | 0.120 |
Why?
| | Adrenergic beta-Agonists | 1 | 2015 | 126 | 0.120 |
Why?
| | Cyclic GMP | 2 | 2011 | 80 | 0.120 |
Why?
| | Capillaries | 1 | 2014 | 91 | 0.110 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2013 | 58 | 0.110 |
Why?
| | Logistic Models | 4 | 2020 | 1840 | 0.110 |
Why?
| | Hospitalization | 2 | 2021 | 1749 | 0.110 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 19 | 0.110 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 305 | 0.110 |
Why?
| | Ligation | 1 | 2012 | 75 | 0.100 |
Why?
| | Vitamins | 1 | 2014 | 151 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 535 | 0.100 |
Why?
| | Ductus Arteriosus | 1 | 2012 | 67 | 0.100 |
Why?
| | Diaphragm | 2 | 2023 | 33 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3408 | 0.100 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 531 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1629 | 0.100 |
Why?
| | Pyridines | 2 | 2012 | 425 | 0.100 |
Why?
| | Amides | 1 | 2012 | 86 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 313 | 0.100 |
Why?
| | DNA Primers | 1 | 2012 | 510 | 0.100 |
Why?
| | Protein Binding | 1 | 2016 | 1889 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 433 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1016 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2018 | 3003 | 0.090 |
Why?
| | Vitamin D | 1 | 2014 | 341 | 0.090 |
Why?
| | Isoenzymes | 1 | 2011 | 283 | 0.090 |
Why?
| | Ultrasonography, Prenatal | 2 | 2022 | 235 | 0.090 |
Why?
| | Prognosis | 3 | 2023 | 3328 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 800 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 797 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 153 | 0.090 |
Why?
| | Blotting, Western | 1 | 2012 | 1147 | 0.090 |
Why?
| | Hypoxia | 1 | 2016 | 957 | 0.090 |
Why?
| | Vasodilation | 2 | 2011 | 419 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.080 |
Why?
| | Myosin-Light-Chain Phosphatase | 1 | 2008 | 3 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 950 | 0.080 |
Why?
| | Dipeptides | 1 | 2008 | 48 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 299 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2017 | 2128 | 0.080 |
Why?
| | Incidence | 3 | 2019 | 2311 | 0.080 |
Why?
| | Phosphorylation | 2 | 2011 | 1569 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1538 | 0.070 |
Why?
| | Nitroarginine | 1 | 2007 | 47 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 750 | 0.070 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 209 | 0.070 |
Why?
| | Oxadiazoles | 3 | 2011 | 32 | 0.070 |
Why?
| | Vascular Resistance | 3 | 2013 | 337 | 0.070 |
Why?
| | Child, Preschool | 2 | 2020 | 9108 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2006 | 115 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 758 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 480 | 0.060 |
Why?
| | Hyperoxia | 1 | 2006 | 99 | 0.060 |
Why?
| | Phenotype | 2 | 2016 | 2796 | 0.060 |
Why?
| | Fetal Development | 1 | 2007 | 246 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 953 | 0.060 |
Why?
| | Cell Membrane | 1 | 2008 | 680 | 0.060 |
Why?
| | Liver | 2 | 2022 | 1634 | 0.060 |
Why?
| | Indomethacin | 1 | 2023 | 70 | 0.050 |
Why?
| | Ketanserin | 2 | 2013 | 12 | 0.050 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.050 |
Why?
| | Sertraline | 2 | 2013 | 26 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1578 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2022 | 78 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2022 | 26 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 425 | 0.050 |
Why?
| | Adult | 3 | 2022 | 30528 | 0.050 |
Why?
| | Young Adult | 1 | 2016 | 10455 | 0.050 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2021 | 116 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 2967 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 134 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 60 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 7 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 186 | 0.040 |
Why?
| | Intubation | 1 | 2018 | 4 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 126 | 0.040 |
Why?
| | Oligohydramnios | 1 | 2018 | 8 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2022 | 534 | 0.040 |
Why?
| | Polyhydramnios | 1 | 2018 | 17 | 0.040 |
Why?
| | Apgar Score | 1 | 2018 | 16 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
| | Heart | 1 | 2022 | 612 | 0.040 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 39 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 147 | 0.040 |
Why?
| | Time Factors | 2 | 2020 | 6112 | 0.040 |
Why?
| | Surgical Mesh | 1 | 2018 | 40 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 99 | 0.040 |
Why?
| | Pneumonia | 2 | 2018 | 567 | 0.040 |
Why?
| | Adolescent | 1 | 2016 | 17831 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 73 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 125 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 167 | 0.040 |
Why?
| | Catheterization, Central Venous | 1 | 2018 | 83 | 0.040 |
Why?
| | Age of Onset | 1 | 2018 | 445 | 0.040 |
Why?
| | Gene Expression | 2 | 2013 | 1421 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 511 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2017 | 99 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 122 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 467 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 935 | 0.030 |
Why?
| | United States | 3 | 2018 | 12176 | 0.030 |
Why?
| | Postpartum Period | 1 | 2019 | 278 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 233 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 1842 | 0.030 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 94 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 385 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 440 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2015 | 14 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 720 | 0.030 |
Why?
| | Calcifediol | 1 | 2015 | 29 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2016 | 76 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1372 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2020 | 712 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 821 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 172 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 771 | 0.030 |
Why?
| | Amniotic Fluid | 1 | 2014 | 64 | 0.030 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 129 | 0.030 |
Why?
| | Sheep, Domestic | 1 | 2013 | 33 | 0.030 |
Why?
| | Tryptophan Hydroxylase | 1 | 2013 | 52 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2894 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 336 | 0.030 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 190 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1430 | 0.030 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 671 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 4894 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 10 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 24 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 32 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 64 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2011 | 93 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 46 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1767 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 560 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1214 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 149 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 220 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 288 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 398 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 854 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 304 | 0.020 |
Why?
| | Piperazines | 1 | 2011 | 309 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 63 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2249 | 0.020 |
Why?
| | Acetylcholine | 1 | 2009 | 166 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 868 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 411 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 434 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1230 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 868 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2076 | 0.010 |
Why?
|
|
Gien's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|